"Drug Approval" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.
Descriptor ID |
D017277
|
MeSH Number(s) |
E05.337.300 I01.880.604.605.250.250
|
Concept/Terms |
Drug Approval- Drug Approval
- Approval, Drug
- Approvals, Drug
- Drug Approvals
- Food and Drug Administration Drug Approval
Drug Approval Process- Drug Approval Process
- Approval Process, Drug
- Approval Processes, Drug
- Drug Approval Processes
- Process, Drug Approval
- Processes, Drug Approval
New Drug Approval- New Drug Approval
- Approval, New Drug
- Approvals, New Drug
- Drug Approval, New
- Drug Approvals, New
- New Drug Approvals
|
Below are MeSH descriptors whose meaning is more general than "Drug Approval".
Below are MeSH descriptors whose meaning is more specific than "Drug Approval".
This graph shows the total number of publications written about "Drug Approval" by people in this website by year, and whether "Drug Approval" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 0 | 1 | 1 |
2009 | 1 | 0 | 1 |
2013 | 0 | 1 | 1 |
2014 | 1 | 0 | 1 |
2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Approval" by people in Profiles.
-
Garmendia CA, Nassar Gorra L, Rodriguez AL, Trepka MJ, Veledar E, Madhivanan P. Evaluation of the Inclusion of Studies Identified by the FDA as Having Falsified Data in the Results of Meta-analyses: The Example of the Apixaban Trials. JAMA Intern Med. 2019 04 01; 179(4):582-584.
-
Jiang P, Mukthavaram R, Mukthavavam R, Chao Y, Bharati IS, Fogal V, Pastorino S, Cong X, Nomura N, Gallagher M, Abbasi T, Vali S, Pingle SC, Makale M, Kesari S. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. J Transl Med. 2014 Jan 17; 12:13.
-
Herzog TJ, Armstrong DK, Brady MF, Coleman RL, Einstein MH, Monk BJ, Mannel RS, Thigpen JT, Umpierre SA, Villella JA, Alvarez RD. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol. 2014 Jan; 132(1):8-17.
-
Younis MM, Younies H, Kisa A, Hartmann M, Hussain AA, Al-Amro A. A review of the effect of pharmaceutical firm drug announcements on stock option pricing. J Health Care Finance. 2009; 35(3):35-43.
-
Davidson MB, Bate G, Kirkpatrick P. Exenatide. Nat Rev Drug Discov. 2005 Sep; 4(9):713-4.